Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Lyell Immunopharma, Inc.

Get SEC filing alerts via email and in your feed for Lyell Immunopharma, Inc.

LYEL

Lyell Immunopharma, Inc.

About Lyell Immunopharma, Inc.

Lyell Immunopharma is a biopharmaceutical company specializing in developing next-generation autologous CAR T-cell therapies for cancer. Its focus includes hematologic malignancies like B-cell lymphomas and solid tumors, utilizing proprietary technologies to enhance T-cell potency, durability, and resistance to exhaustion. The company owns manufacturing facilities and a robust intellectual property portfolio, aiming to deliver innovative, long-lasting cancer treatments through strategic collaborations and advanced cell therapy platforms.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Lyell Immunopharma, Inc.

1
1
Lyell Immunopharma, Inc. Lyell Immunopharma Reports $24.2 Million Net Loss, Advances Clinical Pipeline

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Lyell Immunopharma, Inc. Lyell Immunopharma Reports $274.4 Million Net Loss for 2025, Decreases in R&D Expenses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Lyell Immunopharma, Inc. Lyell Immunopharma Reports $38.8 Million Net Loss in Q3 2025, Revenue Declines

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Lyell Immunopharma, Inc. Lyell Immunopharma Reports $42.7 Million Net Loss in Q2 2025, Revenue Declines

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Lyell Immunopharma, Inc. Lyell Immunopharma Reports Revenue Increase and Reduced Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Lyell Immunopharma, Inc. Lyell Immunopharma Reports $342.99 Million Net Loss and Acquires ImmPACT Bio USA Inc.

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Lyell Immunopharma, Inc. Lyell Immunopharma Reports Mixed Q3 Results, Net Loss Narrows Amid Acquisition and Cost-Cutting Efforts

Via official filing (AI summary) | over 1 year ago | 0 comments